GI CANCERS

The same high cure rates achieved with preoperative chemoradiation can be achieved with preoperative FOLFOX, according to Deb Schrag, MD, FASCO, MPH.

Results from the phase 2b HERIZON-BTC-01 trial presented at ASCO reveal positive efficacy and safety in patient with advanced biliary tract cancer who received zanidatamab.

The phase 3 RATIONALE-306 study displayed encouraging survival and safety data among patients with advanced or metastatic esophageal squamous cell carcinoma who were treated with tislelizumab and chemotherapy.

NALIRIFOX improved overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma.

Development of PYX-201 in advanced solid tumors is underway, and the drug has grabbed the FDA's attend with a phase 1 study in pancreatic cancer.

An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

The new DNA methylation-based PDACatch assay has received a breakthrough device designation from the FDA to detect patients at high-risk for pancreatic adenocarcinoma.

In an interview with Targeted Oncology, Ken Kato, MD, PhD, discussed background and findings from the phase 3 CheckMate 648 trial among patients with esophageal squamous cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Kim, MD, discussed regimens for biliary tract cancers including the results of the TOPAZ-1 trial of additional durvalumab.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE161, a potent, selective, small-molecule inhibitor of PARG, is being evaluated in a phase 1 clinical trial for advanced solid tumors.

At the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.

The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.

The FDA plans to conduct a speedy review of an approval application for trifluridine plus tipiracil and bevacizumab for the treatment of metastatic colorectal cancer.

In an interview with Targeted Oncology for Esophageal Cancer Awareness Month, Arturo Loaiza-Bonilla, MD, MSEd, discussed the pressing need to keep up with the developments in targeted therapies for esophageal and GEJ cancers.

In an interview with Targeted Oncology, Olumide B. Gbolahan, MBBS, MSc, commented on studies that support the use of ctDNA to guide treatment decisions in the adjuvant setting for patients with colorectal cancer.

KEYNOTE-859 findings are under review by the FDA as the regulatory body considers an approval application for pembrolizumab plus chemotherapy for the treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

According to a phase 1b study, ibrutinib can modulate immune response and lead to some promising immune effects for patients with metastatic pancreatic ductal adenocarcinoma.

Based on findings from a phase 1 trial, osemitamab has gained an orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.

PBP1510 has received a fast track designation from the FDA for patients with unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least 1 prior line therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.

A phase 1 study is investigating anti-TIGIT therapy combined with immune checkpoint inhibition for the patients with metastatic microsatellite stable colorectal cancer.

Patrick Wagner, MD, director of complex general surgical oncology at AHN Cancer Institute, discussed the current state of important developments in treatment of gallbladder cancer.

A phase 1 dose-escalation and -expansion clinical trial will evaluate BA3182, a potential anticancer therapy, for patients with advanced adenocarcinoma based on the clearance of an investigational new drug application from the FDA.

A read out from the phase 3 KEYNOTE-859 at the February ESMO Virtual Plenary hints pembrolizumab/chemotherapy is a new treatment choice for locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Treatment with an anti-VEGF tyrosine kinase inhibitor appears safe for patients with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Treatment with futibatinib is now available for patients with previously treated, unresectable, locally advanced or metastatic intrahepatic FGFR2-muatant cholangiocarcinoma.

In an interview with Targeted Oncology™, Nathan Bahary, MD, PhD, discussed adapting to new therapy options and what the future holds for improving care for patients with cholangiocarcinoma.

In an interview with Targeted Oncology, Zev A. Wainberg, MD, discussed the rationale behind NAPOLI 3 and how findings from the study will influence the metastatic pancreatic ductal adenocarcinoma space moving forward.